ArticleBMJ open ophthalmology2018
The Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for the treatment of chronic diabetic macular oedema in vitrectomised eyes: a retrospective study.
Article in BMJ open ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04215445 (Effect of Sodium Glucose co Transporter 2), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Sodium Glucose co Transporter 2 (SGLT2) Inhibition on Optical Coherence Tomography Angiography (OCT-A) Parameters in Diabetic Chronic Kidney Disease (CKD)
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial.Diabetes, obesity & metabolism · 2025Trial
- Sodium-glucose cotransporter 2 inhibitor therapy reduces the administration frequency of steroid injection in patients with diabetic macular edema: A cohort study using the Japanese health insurance claims database.Journal of diabetes investigation · 2024Article
- The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium-Glucose Transporter 2 Inhibitors.Diabetes · 2024Article
- Current Treatments for Diabetic Macular Edema.International journal of molecular sciences · 2023Review
- Application of Proteomics Analysis and Animal Models in Optic Nerve Injury Diseases.Brain sciences · 2023Review
- Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?Journal of clinical medicine · 2022Review
- Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients withLife (Basel, Switzerland) · 2022Article
- Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes.BMJ open diabetes research & care · 2022Article
- Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Review
- Commentary: Oral management of diabetic retinopathy.Indian journal of ophthalmology · 2021Article
- Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond.Cardiovascular endocrinology & metabolism · 2021 · on this mapReview
- Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema.Case reports in ophthalmological medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the change of chronic diabetic macular oedema (DMO) in vitrectomised eyes when the administration of sodium-glucose cotransporter 2 (SGLT2) inhibitors is initiated as a systemic medical treatment. METHODS AND ANALYSIS: This study involved 10 eyes of five patients with chronic DMO lasting more than 6 months who had previously undergone vitrectomy and whose systemic medical treatments were newly changed to SGLT2 inhibitors. In this study, chronic DMO was defined as persistent diffuse macular oedema despite ophthalmic treatment in patients with diabetes. Patients who received antivascular endothelial growth factor therapy or steroids administration, or change of eye-drop medication from at 3 months before and after the initiation of SGLT2 inhibitors, were excluded. In this study, visual acuity (VA) and central retinal thickness (CRT, μm) prior to and at 3, 6 and 12 months after the initiation of SGLT2 inhibitors were retrospectively compared. The Wilcoxon signed-rank test was used for statistical analysis.
resultsIn the 10 treated eyes, from at baseline to at 3, 6 and 12 months after the initiation of SGLT2 inhibitor, median VA (logMAR) improved from 0.35 to 0.15 (p=0.038), 0.2 (p=0.157) and 0.2 (p=0.096), respectively, and median CRT significantly reduced from 500.5 µm to 410 µm (p<0.01), 378 µm (p<0.01) and 339 µm (p<0.01), respectively.
conclusionAlthough this study involved only five patients, our findings indicate that SGLT2 inhibitors might have structural efficacy for chronic DMO in vitrectomised eyes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.